Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis [Yahoo! Finance]
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Yahoo! Finance
Patients completing the initial 24-week treatment will be invited to participate in a 24-week blinded extension period, during which all participants will receive COYA 302 The ALSTARS Trial will enroll 120 ALS participants at approximately 25 centers in the United States and Canada HOUSTON Sept. 22, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov Identifier: NCT 07161999). Coya Therapeutics Logo (PRNewsfoto/Coya Therapeutics, Inc.) Eligible study participants will be randomized to receive one of two different doses of COYA 302 or placebo in this 24-week, double-b
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences [Yahoo! Finance]Yahoo! Finance
- ReAlta Life Sciences Appoints Dr. Howard Berman as Executive ChairmanBusiness Wire
- Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials ConferencesBusiness Wire
- Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Coya Therapeutics (NASDAQ:COYA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=COYA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
COYA
Earnings
- 11/12/25 - Miss
COYA
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 10/27/25 - Form 8-K
- COYA's page on the SEC website